BioArctic announced it has signed an $800 million research and collaboration agreement with Eli Lilly aimed at improving brain delivery. The deal combines BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate. The agreement signals Lilly’s continued focus on addressing CNS exposure challenges—a recurring bottleneck for drug developers pursuing targets in the brain. By tying a technology platform to an internal candidate, the companies are effectively betting that delivery improvements can unlock therapeutic activity. For BioArctic, the deal further validates BrainTransporter as a partnering asset with clear monetization pathways via milestones. It also adds to the broader CNS delivery toolkit race among biotechs and pharma, where technology access can shorten timeline risk. While the specific target and mechanism were not disclosed, the size of the commitment underscores the expected strategic importance of enabling CNS delivery for the selected Lilly candidate.